drugset / Trial / NCT05295394
Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.
Timeline
- Start
- 2019-05-22
- Primary completion
- 2022-08
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |